百奥赛图在2024年实现了自2021年以来的首次盈利,全年净利润为3354万元,成功扭亏为盈。在猴价暴跌、CRO普遍承压的2024年,百奥赛图盈利的秘诀又是什么呢?以下是医药财经AI从多维度分析:1. 核心业务增长驱动收入提升抗体开发业务进入收获期:百奥赛图的“千鼠万抗”计划在2024年进入订单转化阶段,全年抗体转让业务收入达3.18亿元,同比增长80.7%,新增签署合作约100项(+70%)。该...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.